News Release

The uncharted role of HER2 mutant alleles in breast cancer

Peer-Reviewed Publication

Impact Journals LLC



The uncharted role of HER2 mutant alleles in breast cancer

view more 

Credit: 2023 Kalra et al.

“Our research study has demonstrated that poziotinib is highly potent in neratinib-resistant HER2 L755S lobular and ductal breast cancer models [...].”

BUFFALO, NY- November 6, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on October 31, 2023, entitled, “The uncharted role of HER2 mutant alleles in breast cancer.”

Somatic HER2 mutations are a novel class of therapeutic targets across different cancer types. Treatment with the tyrosine kinase inhibitor (TKI) neratinib as a single agent continues to be evaluated in HER2-mutant metastatic disease. However, responses are heterogeneous, with frequent early progression. 

In this new editorial, researchers Rashi Kalra, Bora Lim, Matthew J. Ellis, and Shyam M. Kavuri from Baylor College of Medicine discuss the under-explored effects of individual HER2 mutant alleles on therapeutic response, a role for HER2 mutation in metastatic propensity, and differences in patient outcomes in ER+ invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC). The preclinical efficacy of additional agents is also discussed, particularly the pan-HER inhibitor poziotinib.

“In summary, preclinical findings described above support clinical investigation of poziotinib in a subset of ER + mBC harboring HER2 somatic mutations and suggest further studies to evaluate poziotinib as a therapeutic agent in additional tumor types.”

Read the full paper: DOI: 

Correspondence to: Shyam M. Kavuri


Keywords: metastasis, poziotinib, HER2, neratinib, invasive lobular breast carcinoma

About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, visit and connect with us on social media:


Sign up for free Altmetric alerts about this article: 

Click here to subscribe to Oncotarget publication updates.

For media inquiries, please contact:


Oncotarget Journal Office

6666 East Quaker Str., Suite 1A

Orchard Park, NY 14127

Phone: 1-800-922-0957 (option 2)


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.